Bryan, Garnier & Co's News

Read all the news of the independent investment banking dedicated to Growth
Share on
Filters

Food retailing: FY Ahold (BUY) & Delhaize (Buy): strong end to the year (first take)

Published last March Thursday 3, 2016

Luxottica: Investor Day Feedback: today’s investments are tomorrow’s robust sales and profit growth

BUY, Fair Value EUR65 (+27%)

Published last March Thursday 3, 2016

Jeronimo Martins: FY 2015 (first take): JM is very impressive but also very expensive…

NEUTRAL, Fair Value EUR13,5 (+1%)

Published last March Thursday 3, 2016

bioMérieux: Weak 2016 EBIT guidance provides buying opportunity

BUY, Fair Value EUR121 (+3%)

Published last March Wednesday 2, 2016

Campari: The wind in its sails

BUY vs. SELL, Fair Value EUR8,4 vs. EUR7,1 (+12%)

Published last March Wednesday 2, 2016

Luxottica: FY15 adj. op income 1.5% short of our expectations but a reassuring FY16-18 outlook!

BUY, Fair Value EUR65 (+21%)

Published last March Wednesday 2, 2016
Bryan, Garnier & Co advises the shareholders of Proteines Group on its sale to Equinoa

Bryan, Garnier & Co advises the shareholders of Proteines Group on its sale to Equinoa

Published last February Friday 26, 2016

Afternoon call: LDR Holding

LDR HOLDING - BUY, Fair Value USD41 (+98%)

Published last February Thursday 25, 2016

bioMérieux: FilmArray torch cleared by the FDA with the respiratory panel

(BUY, Fair Value EUR121 (+4%)

Published last February Thursday 25, 2016

Bayer: Disappointing

(NEUTRAL, Fair Value Under Review)

Published last February Thursday 25, 2016

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities